Published in Rinsho Ketsueki on January 01, 1989
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell (1999) 11.59
Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A (1990) 9.98
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science (1999) 7.57
Nucleotide sequence of bacteriophage fd DNA. Nucleic Acids Res (1978) 7.25
Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A (1991) 7.15
CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet (1994) 7.07
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature (1989) 5.86
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Studies on bacteriophage fd DNA. IV. The sequence of messenger RNA for the major coat protein gene. J Mol Biol (1977) 5.34
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol (1999) 4.70
Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem (1996) 4.50
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem (1997) 4.12
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
Mitochondrial myopathies. Ann Neurol (1985) 3.81
Elucidation of the Erwinia uredovora carotenoid biosynthetic pathway by functional analysis of gene products expressed in Escherichia coli. J Bacteriol (1990) 3.78
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology (2010) 3.70
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Iron fortification of rice seed by the soybean ferritin gene. Nat Biotechnol (1999) 3.53
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem (1995) 3.45
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin- mediated cell-cell adhesion. Science (1998) 3.39
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun (1991) 3.09
Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem (1996) 3.05
Phosphorus uptake by pigeon pea and its role in cropping systems of the Indian subcontinent. Science (1990) 3.03
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem (1996) 2.95
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
Sequence of promoter for coat protein gene of bacteriophage fd. Nature (1976) 2.82
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. Ann Surg (1987) 2.69
Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci U S A (1996) 2.68
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol (1997) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
A multistep damage recognition mechanism for global genomic nucleotide excision repair. Genes Dev (2001) 2.59
Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals. Virus Res (1992) 2.56
Characterization of long terminal repeat sequences of HTLV-III. Science (1985) 2.56
Uterine sutures at prior caesarean section and placenta accreta in subsequent pregnancy: a case-control study. BJOG (2014) 2.56
Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am (1998) 2.52
miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer (2010) 2.51
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity (2000) 2.47
Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett (1998) 2.40
Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
Endoscopic ultrasound-guided celiac ganglia neurolysis vs. celiac plexus neurolysis: a randomized multicenter trial. Endoscopy (2013) 2.34
Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem (1997) 2.34
New cephalosporin derivatives with high antibacterial activities. Chem Pharm Bull (Tokyo) (1977) 2.33
Developmental changes in energy substrate use by the heart. Cardiovasc Res (1992) 2.33
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry (2004) 2.32
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood (2000) 2.31
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J Cell Biol (2000) 2.31
Animal research in liver transplantation with special reference to the dog. Semin Liver Dis (1985) 2.28
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
HRT1, HRT2, and HRT3: a new subclass of bHLH transcription factors marking specific cardiac, somitic, and pharyngeal arch segments. Dev Biol (1999) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer (2011) 2.25
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am (1998) 2.18
Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation (1995) 2.15
Reevaluation of the thyroidal radioactive iodine uptake test, with special reference to reversible primary hypothyroidism with elevated thyroid radioiodine uptake. J Clin Endocrinol Metab (1988) 2.15
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem (1993) 2.14
Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system. Cell (1986) 2.13
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
Diastolic paradoxic jet flow in patients with hypertrophic cardiomyopathy: evidence of concealed apical asynergy with cavity obliteration. J Am Coll Cardiol (1992) 2.12